Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabotegravir
- Development stage
- Approved
- Lead developer
- ViiV Healthcare
- Modality
- Small Molecules
- Administration
- Intramuscular, Oral
01
Overview
Cabotegravir is a small molecule antiretroviral drug classified as an integrase strand transfer inhibitor (INSTI). It is used for both the treatment and pre-exposure prophylaxis (PrEP) of HIV type 1 infection. Its mechanism of action involves binding to the active site of HIV integrase, thereby preventing the integration of viral DNA into the host genome, which is essential for viral replication. Cabotegravir is available as an oral tablet and as a long-acting intramuscular injection. For HIV treatment, it is always used in combination with rilpivirine; for PrEP, it can be used alone. The drug was developed by ViiV Healthcare and has been approved by regulatory agencies including the FDA for use in adults and adolescents at risk of or living with HIV[1][2][3][5][8].
- Brand names
- ApretudeVocabria
- Other names
- Cabotegravir sodiumCabotegravir (JAN/USAN/INN)Cabotegravir(GSK744)SCHEMBL82803SCHEMBL-82803SCHEMBL 82803CHEMBL2403238CHEMBL-2403238CHEMBL 2403238
02
Targets
SLC22A8 (Organic anion transporter 3)Integrase allosteric pocket (HIV)OAT1 (Organic anion transporter 1)HTLV-1 IN (HTLV-1 integrase)
Beyond the preview
Go deeper on cabotegravir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabotegravir.